Targeted protein degradation, oncology research, and biotech innovation by C4 Therapeutics
C4 Therapeutics expands discovery platform to accelerate development of molecular glue degraders
C4 Therapeutics has expanded its discovery platform to help identify novel molecular glue degraders. The company is using its DNA-encoded library (DEL) to create an efficient hit-finding engine ...
Cemsidomide trial yields new biomarker data, C4 Therapeutics reports
C4 Therapeutics has presented a poster revealing new biomarker data from its cemsidomide clinical trials at IMS26. This update highlights ongoing research efforts and provides fresh insights into ...
C4 Therapeutics presents new biomarker data on cemsidomide at IMS26
C4 Therapeutics announced it will present new biomarker data at IMS26, focusing on the immunomodulatory effects of cemsidomide combined with dexamethasone from its Phase 1 trial. Cemsidomide is ...
Employee wellness programs expanded as C4 Therapeutics, Inc. invests in team wellbeing
C4 Therapeutics, Inc. is implementing a comprehensive approach to employee wellbeing with new company-wide initiatives. The biopharmaceutical company offers its staff two company-wide shutdowns ...
C4 Therapeutics Inc. celebrates Project Onramp interns for summer achievements
C4 Therapeutics Inc. recognized its interns at the annual Project Onramp Internship Summit. The company congratulated Edelmis, Maryam, and Andy for their contributions and learnings while ...
Second quarter 2026 earnings and business update released by C4 Therapeutics, Inc.
C4 Therapeutics, Inc. published its financial results for the second quarter of 2026 alongside recent business updates. The company shared highlights via its latest press release, offering ...
C4 Therapeutics, Inc. welcomes science creators at U.S. Science Summit to present TPD pipeline
C4 Therapeutics, Inc. hosted a group of science creators as part of the U.S. Science Summit, providing them with insights into its targeted protein degradation (TPD) pipeline. The event allowed ...
Andrea Martin drives innovative science and mentorship at C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is moving forward in its discovery biology efforts as Andrea Martin, Ph.D., vice president, leads initiatives to expand the company’s investigational new drug (INN) ...
C4 Therapeutics presents data on cemsidomide plus dexamethasone trial at EHA2026
C4 Therapeutics revealed new analysis from its fully enrolled Phase 1 trial studying cemsidomide in combination with dexamethasone for patients with relapsed or refractory multiple myeloma at ...
Executive team at C4 Therapeutics, Inc. set for Jefferies conference fireside chat
C4 Therapeutics, Inc. announced its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference. The session is scheduled for June 4 at 9:20 am ET. The ...
C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26
C4 Therapeutics, Inc. announced plans to present a Trial in Progress poster at ASCO26, focusing on its Phase 2 MOMENTUM clinical trial of cemsidomide. The therapy is a potential best-in-class ...
Clinical trial participation drives development of innovative treatments, C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is emphasizing the essential role of clinical research and patient participation in the development of new medicines. The company reaffirmed its commitment to innovative ...
C4 Therapeutics, Inc. to present new cemsidomide Phase 1 data at EHA Hematology 2026 Congress
C4 Therapeutics, Inc. announced it will present a poster with further analysis from its Phase 1 study of cemsidomide, a potential best-in-class IKZF1/3 degrader, in combination with dexamethasone ...
